Alivus Life Sciences Ltd. News and Updates

Name: Latest research reports of Alivus Life Sciences Ltd. authored by Angel Broking and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: Angel Broking

Keep track of all breaking news on Alivus Life Sciences Ltd. from all sources in a single place.

Load latest

Alivus Life Sciences Ltd.

26 Jul 2021

944.70

-1.04%

GLENMARK LIFE SCIENCES LIMITED

IPO Subscribe: Alivus Life Sciences Ltd.

Angel Broking

Glenmark Life Sciences Limited (GLS) was incorporated on 23rd June, 2011. GLS is a wholly-owned subsidiary of the Promoter, Glenmark Pharmaceuticals Ltd. GLS operates two business lines Generic APIs (generics and complex APIs) and CDMO (including specialty). GLS is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in

Alivus Life Sciences.. has an average target of 1317.00 from 1 broker.

Alivus Life Sciences Ltd.

26 Jul 2021

944.70

-1.04%

Glenmark Life Sciences Ltd. IPO Note

IPO Note: Alivus Life Sciences Ltd.

Ashika Research

20 Equity Shares and in multiples thereof. Public issue of 21,022,222 Equity shares of Face value Rs. 2 each, (Comprising of fresh issue of 14,722,222 Equity Shares* (Rs. 1060 cr.) and Offer for Sale of...

Alivus Life Sciences Ltd. has lost -26.43% in the last 1 Year

Alivus Life Sciences Ltd.

24 Jul 2021

944.70

-1.04%

Glenmark Life Sciences

IPO Note: Alivus Life Sciences Ltd.

AUM Capital

Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...

Alivus Life Sciences Ltd. has lost -26.43% in the last 1 Year

Alivus Life Sciences Ltd.

24 Jul 2021

944.70

-1.04%

GLENMARK LIFE SCIENCES LTD

IPO Note: Alivus Life Sciences Ltd.

Ventura

IPO NOTE

Alivus Life Sciences Ltd. is trading below all available SMAs

Alivus Life Sciences Ltd.

23 Jul 2021

944.70

-1.04%

Glenmark Life Sciences Ltd : IPO

IPO Note: Alivus Life Sciences Ltd.

ICICI Securities Limited

Leadership in select APIs, strong relation with large companies GLS is a leading developer, manufacturer of select high value, noncommoditised APIs in chronic therapeutic areas, including CVS, CNS & pain management, diabetes and continue to branch into other APIs. It has strong market share in select specialised APIs like Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). Total market size in sales terms for GLS' portfolio of 120 molecules globally was estimated at ~US$142 billion in 2020 and is expected to grow ~6.8% in the...

Alivus Life Sciences Ltd. has lost -26.43% in the last 1 Year

VOTE: Is Glenmark Life Sciences Ltd. worth buying?

132 Votes:

Buy 75.0%

Sell 12.12%

Hold 12.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf

29.24% Fall from 52W High

Alivus Life Sciences Ltd. News and Updates

Keep track of all breaking news on Alivus Life Sciences Ltd. from all sources in a single place.